Claim Missing Document
Check
Articles

Found 33 Documents
Search

The hidden grip: A case of secondary hypertension entwined with renal artery stenosis Rahmawati, Novi; Handari, Saskia Dyah; Hargiyanto, Erlangga Diasmara
Heart Science Journal Vol. 7 No. 1 (2026): Accelerating Clinical Breakthroughs: The Journey from Molecular Discovery to Pa
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.01.20

Abstract

Background: Renal artery stenosis (RAS) is a vascular disorder characterized by narrowing of the renal artery. It often leads to renovascular hypertension (RVH) and, if untreated, progression to end-stage renal disease. Atherosclerosis and fibromuscular dysplasia (FMD) are the most common etiologies, with clinical manifestations ranging from asymptomatic to resistant hypertension. Diagnosis involves imaging modalities such as Doppler ultrasound (DUS), CT angiography (CTA), and confirmation by digital subtraction angiography (DSA). We report a case to emphasize the diagnostic and therapeutic challenges of RAS in young patients. Case Illustration: A 17-year-old male presented with persistent grade 2 hypertension unresponsive to dual antihypertensive therapy and a history of repeated hospitalizations. Imaging revealed significant stenosis with post-stenotic dilatation in the right renal artery. CTA and DSA confirmed the diagnosis of RVH secondary to RAS, with Fibromuscular Dysplasia (FMD) as the suspected etiology. The patient underwent successful angioplasty and stenting, resulting in improved blood pressure control and reduced medication requirements. Upon follow-up, the patient’s symptoms have resolved, and their blood pressure is under control. RAS remains a challenging and underdiagnosed cause of secondary hypertension, particularly in younger patients. While optimal medical therapy is the first-line approach, it may be insufficient in high-risk individuals. Non-invasive modalities provide valuable initial assessment, but DSA remains the gold standard for diagnosis and intervention. Revascularization, especially via stenting, is recommended in selected cases with significant stenosis, viable renal tissue, and resistant hypertension. Guidelines emphasize tailored therapy and careful post-procedure monitoring to detect restenosis or symptom recurrence. This case underscores the importance of early recognition and individualized intervention to improve outcomes.. Conclusions: RAS should be considered in young patients with grade 2 hypertension. Early diagnosis and appropriate intervention are critical to preventing long-term renal and cardiovascular complications.
Analisis Penyakit Tuberkulosis (TBC) pada Provinsi Jawa Timur Tahun 2021 Menggunakan Geographically Weighted Regression (GWR) Rahmawati, Novi; Karno, Faldianus; Hermanto, Elvira Mustikawati Putri
Indonesian Journal of Applied Statistics Vol 6, No 2 (2023)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.13057/ijas.v6i2.78593

Abstract

Tuberculosis (TB) is an infectious disease with the highest mortality rate in the world. In East Java, TB cases will experience a significant increase in 2021. This study uses the Geographically Weighted Regression (GWR) method to analyze the variables that affect TB cases in East Java that year. The variables used are the number of TB cases, the number of smokers, the number poor population, and population density. The GWR results show that the number of poor people has a significant effect on all districts/cities in East Java. Meanwhile, population density has a significant effect in most areas (except Pacitan, Bondowoso, Situbondo). This research provides input for the government to reduce the number of TB cases in East Java. Efforts need to be made to increase employment and reduce regional disparities so that the burden of this disease can be controlled more effectively.Keywords: TBC, GWR, Kernel Bisquare
Antiarrhythmic properties and mechanisms of SGLT2 inhibitors in managing atrial fibrillation patients with metabolic syndrome Rahmawati, Novi; Rizal, Ardian; Putri, Diana Yuswanti
Heart Science Journal Vol. 7 No. 3 (2026): Predicting Restenosis in Coronary Artery Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.03.3

Abstract

Atrial fibrillation (AF) frequently occurs in patients with metabolic syndrome (MetS), a cluster of cardiometabolic abnormalities including obesity, hypertension, dyslipidemia, and type 2 diabetes mellitus (T2DM), which collectively promote adverse atrial electrical and structural remodeling. These intertwined conditions significantly complicate AF management and contribute to disease progression. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, initially developed as glucose-lowering agents, have demonstrated robust cardiovascular and renal benefits beyond glycemic control. Accumulating clinical evidence from post-hoc analyses, real-world studies, and large meta-analyses indicates that SGLT2 inhibitors significantly reduce the incidence of new-onset and recurrent AF, particularly in patients with MetS and T2DM. Mechanistic studies revealed that the antiarrhythmic effects of SGLT2 inhibitors arise from pleiotropic actions targeting key arrhythmogenic pathways. These include restoration of intracellular Na⁺ and Ca²⁺ homeostasis via inhibition of the Na⁺/H⁺ exchanger and CaMKII signaling, suppression of oxidative stress and inflammation through modulation of NADPH oxidase and NLRP3 inflammasome activity, attenuation of atrial fibrosis by inhibiting the TGF-β/Smad pathway, and improvement of mitochondrial function and bioenergetics through activation of the PGC-1α/NRF-1/Tfam axis. Additional systemic benefits, such as weight reduction, improved hemodynamics, decreased epicardial adipose tissue, and autonomic nervous system modulation, further contribute to atrial electrical stability. This review summarizes current clinical and mechanistic evidence supporting the role of SGLT2 inhibitors as a promising upstream therapeutic strategy for AF prevention and management in patients with MetS.